type I interferons – Page 2 – Communicable Diseases Research

Anti-MDA5 Antibody Linking COVID-19, Type I Interferon, and Autoimmunity: A Case Report and Systematic Literature Review

COVID-19, I형 인터페론 및 자가면역을 연결하는 항MDA5 항체: 증례 보고 및 체계적인 문헌 검토

Case Reports

Published on 2022-06-272022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커,

JAK inhibitors and COVID-19

JAK 억제제 및 COVID-19

Review

Published on 2022-04-012022-09-11
Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), SARS, 진단, 치료제,

[키워드] activated added Antiviral antiviral molecules Autoimmunity Baricitinib benefit clinical experience clinical trials coded concerning contributing to COVID-19 COVID-19 treatment cut-off cytokine Cytokine storm Cytokines differentiation Effect Effects Evolution family Graft hematologic hematologic neoplasms Human genome immune regulation immune response Immunosuppression immunosuppressive effect immunosuppressive effects indicated induce inhibited innate immune response interferons involved issue Jak JAK inhibitor jak inhibitors JAK1 JAK2 JAK3 JAKi janus Janus kinase kinases Meta-analysis moment Neoplasms nezulcitinib outcome pathogenic pathway Pathways patients treated patients with COVID-19 Phase 3 trials proliferation randomized clinical trial RCT reaction receptor reduce mortality rheumatic disease Rheumatic diseases risk reduction ruxolitinib SARS-COV-2 infection severe COVID-19 Side effect Signaling Significant Standard of care subsequent suggested survival the SARS-CoV-2 the WHO Therapies therapies, investigational. Tofacitinib transmembrane Treatment trials TYK2 Type I IFN type I interferons Viral viral replication virus clearance
[DOI] 10.1136/jitc-2021-002838 PMC 바로가기 [Article Type] Review

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?

감소된 수의 형질세포양 수지상 세포가 만성 림프구성 백혈병에서 COVID-19의 공격적인 임상 경과에 기여합니까?

Review

Published on 2022-04-012022-09-11
Journal: Scandinavian journal of immunology [Category] COVID19(2023년), SARS, 유전자 메커니즘,

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

특정 체액 면역이 없는 1차 항체 결핍 환자의 중증 및 치명적인 COVID-19에서 SARS-CoV-2 T 세포 반응

Article

Published on 2022-03-102022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, 치료법,

[키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Analysis analyzed antibody autoantibodies autoantibody Blood CD169 CD4 cellular characterized clearance clinical disease Comorbidities Comorbidity convalescent convalescent plasma Convalescent plasma (CP) coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 cytokine deficiency detectable elevated examined excluded expression fatal COVID-19 flow cytometry healthy individuals heterogeneous humoral humoral immune response IgG Immunity immunodeficiency immunological immunological mechanism Inborn errors indicate innate immune response Innate immunity interferon interferons lack marker median monoclonal antibody Monocytes morbidity Mortality mucosal naïve nucleocapsid outcome Patient patients peptide peptide pool Peripheral blood persistence phenotype primary antibody primary antibody deficiency (PAD) Primary immunodeficiencies primary immunodeficiencies (PID) producing Prophylactic respiratory response Risk factors robust SARS-CoV-2 SARS-CoV-2 immunity SARS-CoV-2 RNA SARS-CoV-2 spike SARS-CoV-2 viral shedding seronegative severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Severe case severe cases severe COVID-19 patient SIGLEC1 Specific T cell T cell response T cells Treatment type I interferon type I interferon response type I interferons undetectable Viral viral clearance viral shedding with COVID-19
[DOI] 10.3389/fimmu.2022.840126 PMC 바로가기 [Article Type] Article

The cGAS-STING pathway drives type I IFN immunopathology in COVID-19

cGAS-STING 경로는 COVID-19에서 I형 IFN 면역병리를 유발합니다

Article

Published on 2022-03-012022-09-11
Journal: Nature [Category] SARS, 진단, 치료기술, 치료법,

[키워드] activate addition caused cell death cGAS characterized ChIP Clinical outcome Complication Control COVID-19 Critical cyclic GMP cytosolic disease DNA Endothelial cell endothelial cell damage endothelial cells IFNs Immunity immunopathology IMPROVE increase in Infection infection with SARS-CoV-2 Inflammation interferon interferons interferons (IFNs late phase limit lung Lung inflammation Lung pathology Macrophage macrophages Manifestations mice mitochondrial mitochondrial DNA outcome Pathogenesis pathogenesis of COVID-19 pathway patients with COVID-19 pharmacological principle Profiling Rapid induction reduce response responses reveal SARS-CoV-2 severe lung inflammation STING sustained tissue Type Type I IFN type I IFN responses type I IFNs type I interferons virus propagation
[DOI] 10.1038/s41586-022-04421-w PMC 바로가기 [Article Type] Article

Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection

차등 인터페론-α 아형 유도 면역 시그니처는 SARS-CoV-2 감염 억제와 관련이 있습니다

420

Published on 2022-02-072022-09-10
Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단,

[키워드] abundance activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 additive effects Analysis analyzed Antiviral antiviral activity antiviral drug antiviral host response antiviral host responses antiviral response antiviral responses autoantibody Cell culture cellular Clinical treatment coronavirus Course defined disease downstream early administration Effect effector effector molecule epithelial cell epithelial cells Express functional hAEC help Host Human identify IFN-alpha IFN-I IFN-I signaling IFNs IFNα immune immune response immune responses immune signature Immune-mediated Immunity Immunotherapy Inborn error Inborn errors interferon Interferon-α interferons involved knowledge life-threatening negative regulation Pathologies Pathways pleiotropic primary human airway Primary human airway epithelial cells Prophylaxis Protective proteomic Remdesivir respiratory response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2–infected mice severe acute respiratory syndrome Coronavirus signaling cascade Significance subtype Subtypes Support Therapeutic approach therapeutic potential transcriptional transcriptomic analysis Treatment Type type I IFNs type I interferons Viral Viral diseases viral infections virus viruses
[DOI] 10.1073/pnas.2111600119 PMC 바로가기 [Article Type] 420

Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome

치명적인 COVID-19 폐렴과 다기관 염증 증후군이 있는 어린이의 유전성 IFNAR1 결핍

Case Reports

Published on 2022-01-282022-09-10
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

[키워드] autoantibodies autoantibody autosomal recessive candidate gene cause causes Child children contribute COVID-19 COVID-19 pneumonia Critical critical pneumonia Cytokines detect died dysregulation Exome Genetic variant homozygous IFNAR1 IFNAR1 deficiency IFNs Immunity Inborn error inborn errors of immunity (IEI) Inflammatory interferons investigated loss-of-function MIS-C multisystem inflammatory syndrome in children (MIS-C) objective patients Plasma level Plasma levels Pneumonia primary immunodeficiency (PID) raise Result SARS-COV-2 infection Sequencing specific antibodies specific antibody supplementary material syndrome Type I IFN type I IFNs type I interferon type I interferons underlie variant virus was performed
[DOI] 10.1007/s10875-022-01215-7 PMC 바로가기 [Article Type] Case Reports

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital

Original Article

Published on 2022-01-272023-07-02
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), SARS,

[키워드] autoantibodies COVID-19 Mortality type I interferons
[DOI] 10.1007/s10875-021-01203-3 PMC 바로가기 [Article Type] Original Article

The role of NADPH oxidases in infectious and inflammatory diseases

감염성 및 염증성 질환에서 NADPH 산화효소의 역할

Review

Published on 2021-12-012022-09-12
Journal: Redox Biology [Category] MERS, SARS, 진단,

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

무증상 코비드 -19 감염에서 상향 조절 된 유형 I 인터페론 반응은 개선 된 임상 결과와 관련이 있습니다.

Article

Published on 2021-11-252022-09-10
Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 변종, 유전자 메커니즘, 임상, 치료법, 치료제,

[키워드] Antigen presentation approach Asymptomatic Asymptomatic cases Asymptomatic COVID-19 Biomarker Biomarkers blood transcriptome CD177 Clinical outcome Computational biology and bioinformatics COVID-19 COVID-19 case COVID-19 disease disease Disease progression downregulated downregulation dysregulation early response early stage effectively controlled help Host humoral ICAM3 IFN IFNAR2 immunology IMPROVE Infection Inflammatory initial interferon interferons IRF2BP1 IRF2BP2 IRF2BPL IRF4 ISG ISGs limit marker MAVS Microbiology Mild mRNA translation neutrophil pathway Pathways progressive disease protective mechanism protective mechanisms response SAMHD1 SARS-CoV-2 SARS-COV-2 infection severe COVID-19 severity of COVID-19 significantly SOCS3 stimulated suppression symptomatic disease These data TLR8 Transcriptome Treatment type I interferon type I interferons understanding uninfected upregulated upregulation Viral
[DOI] 10.1038/s41598-021-02489-4 PMC 바로가기 [Article Type] Article